MBS significantly reduces liver-related complications and other health risks in patients with SLD, including cardiovascular, ...

Advances in systemic and local therapies are helping more live longer with liver cancer and move forward after treatment as ...

Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...

After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.

Merck and Eisai halt late-stage trial as Keytruda/Lenvima combo fails to improve survival in liver cancer. Read more here.

Discover a study showing how PEth levels identify alcohol use and predict adverse outcomes in MASLD, MetALD, and ALD patients ...

Liver cirrhosis is significantly more common in low-income households than in high-income households, according to a national ...

Liver cirrhosis is significantly more common in low-income households than in high-income households. This is the result of a ...

Hepatocellular carcinoma (HCC) represents a leading cause of cancer-related mortality globally. The advent of immunotherapy, particularly immune checkpoint ...

Angiodynamics, Inc. (($ANGO)) announced an update on their ongoing clinical study. Angiodynamics, Inc. has announced a new clinical study titled ...

As the incidence of obesity continues to rise nationally and globally, a new observational study published in Cancer reports ...